Research Efforts From Entheon Biomedical Suggest Psychedelics’ Potential In Treating Chronic Addictions

Don’t miss this opportunity to connect with THE cannabis movers and shakers from across the globe during Benzinga’s Virtual Cannabis Capital Conference on October 15. Among the attendees is Entheon Biomedical.

Psychedelics is an emerging industry with a lot of potential in the way of drug development and therapy. For many years, psychedelics have been stigmatized for their perceived effects on the human brain. Yet, research is currently being done in this field to demonstrate the promise psychedelics hold in treating chronic additions.

Entheon Biomedical is comprised of a team of researchers who are dedicating their work to the treatment of substance abuse disorders. The company’s research centers around psychedelic analogs and how these pharmaceutical compounds hold great potential in treating chronic addictions. 

“Alcoholism, tobacco addiction, and opioid users are …

Full story available on Benzinga.com

More Research Efforts From Entheon Biomedical Suggest Psychedelics' Potential In Treating Chronic Addictions